Key Issues in the Treatment of Lymphoma: The Role of CD30 in Diagnosis and Management

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 30, 2015
Expiration Date: September 30, 2016

Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

With the advances made in frontline multiagent chemotherapy, Hodgkin lymphoma (HL) is deemed to be a highly curable disease. Nonetheless, advanced HL remains a challenge as 10% of patients will not achieve a complete remission and 20–30% of patients who initially responded will experience a relapse. This activity brings together leading world experts in lymphoma to discuss some of the most talked about issues and ongoing clinical trials in the treatment of HL today.

Since the initial description of monoclonal antibodies against Hodgkin and Sternberg-Reed (HRS) cells in HL, the CD30 antigen has attracted substantial scientific interest as a therapeutic target for malignancies that express this cell surface marker. As for other types of cancer, immunoconjugates or antibody-drug conjugates (ADCs) are part of a growing revolution in selective immunotherapeutic development for cancer, an ever-expanding clinical strategy that has led the way in addressing clinical barriers for HL and anaplastic large cell lymphoma (ALCL) as prime examples. Review what the experts are saying regarding the biology of CD30 and what the current data say about the efficacy of CD30 targeted therapeutic strategies in HL, and the evolving role in the treatment of B-cell and T-cell lymphoma.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline the role of CD30 in HL and T-cell lymphomas based on the current science, and identify the critical pathobiological features of CD30+ lymphoid neoplasms
  • Describe the immunohistochemical assessment of CD30 in patients with HL and T-cell lymphomas, and correlate the results of those assessments with prognosis in both types of lymphomas
  • Formulate and implement a treatment plan for patients with HL, PTCL, or ALCL, taking into account disease histopathology, stage, and relevant patient characteristics
  • Summarize results of clinical trials evaluating new and emerging agents or combinations of agents in the treatment of patients with CD30+ lymphomas, focusing on changes in recommended treatment sequencing that are evolving as a result of new data

Agenda

Advances in CD30 Pathology – Stefano A. Pileri, MD

The Evolving Role of CD30 in B-cell and T-cell Lymphoma – Francesco d’Amore, MD

The Evolving Role of CD30 in Hodgkin Lymphoma – Anas Younes, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 30, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Anton Hagenbeek, MD, PhD – Program Chair
Professor of Hematology
University Medical Center Utrecht
and Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

Dr. Anton Hagenbeek received his medical degree from the Erasmus University in Rotterdam. He was trained in experimental hematology in the Radiobiological Institute T.N.O. in Rijswijk where he obtained his PhD and after training in internal medicine/ hematology in Rotterdam, completed a fellowship in hematology at University of California, Los Angeles (UCLA). Dr. Hagenbeek is a professor of hematology at the University Medical Center Utrecht, The Netherlands, and holds a joint appointment as professor of hematology in the Department of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands.

His main research interests began with developmental therapeutics for leukemia, focusing on translational research from preclinical animal models and in vitro studies to clinical application. From studies on minimal residual disease and experimental bone marrow transplantation (GVHD-GVL), Dr. Hagenbeek then moved into immuno-gene therapy of hematological malignancies. To date, his clinical research activities are mainly in the field of (intergroup) studies in non-Hodgkin’s lymphomas and Hodgkin lymphomas. He has established two (international) consortia dealing with developing new biological prognostic indices in lymphoma and running first-in-man phase I/II studies with new agents in the lymphomas and chronic lymphocytic leukemia (CLL). Dr. Hagenbeek has authored/co-authored 335 papers in peer-reviewed journals.

Francesco d’Amore, MD
Clinical Professor
Malignant Lymphoproliferative Diseases
Department of Haematology
Aarhus University Hospital
Denmark

Dr. Francesco d’Amore received his medical degree from the University of Genoa, Italy, where he also completed his residency. He was a research fellow in the Department of Haematology and Pathology at the University of Odense in Denmark, and was a post-doctoral research associate at the University of Nebraska Medical Center in Omaha. Dr. d’Amore is a clinical professor in malignant lymphoproliferative diseases at the Department of Haematology, Aarhus University Hospital, Denmark, senior registrar, and a consultant haematologist responsible for the lymphoma unit.

Dr. d’Amore is chairman of the Working Group on T-Cell Lymphomas and a member of the coordinating committee of the Nordic Lymphoma Group. His research interests include non-Hodgkin lymphoma with particular focus on T-cell lymphomas as well as Hodgkin lymphoma.

Stefano A. Pileri, MD
Alma Mater Professor of Pathologic Anatomy
Bologna University
Director of the Service of Haematopathology
European Institute of Oncology
Milan, Italy

Dr. Stefano Pileri received his medical degree from Bologna University and completed post-doctoral studies in hematopathology at Kiel University. He had a professorship at Bologna University and full-professorship at Siena University, both in pathologic anatomy. Dr. Pileri is the alma mater professor of pathologic anatomy at Bologna University, and director of the Service of Haematopathology at the European Institute of Oncology in Milan. He is also chief of the haematopathology unit at the Institute of Haematology “L. & A. Seràgnoli” and director of the 2nd Service of Pathologic Anatomy and Histopathology of Bologna University.

Among the founders of the International Lymphoma Study Group, Dr. Pileri is also founder of the Haematopathology Group of SIAPEC-IAP and of the European T-cell Lymphoma Study Group. He is chairperson of the Pathology Co-operative Group of the Italian Academy of Medicine, and the Pathology Panel of the Italian Lymphoma Foundation. Dr. Pileri is also an active member of the Society of Hematopathology, European Association for Haematopathology (EAHP), and European Bone-Marrow Working Group.

Dr. Pileri is an editorial board member/reviewer of the American Journal of Pathology, American Journal of Surgical Pathology, Annals of Oncology, Blood, Cancer, Current Diagnostic Pathology, European Journal of Cancer, General and Diagnostic Pathology, Haematologica, Histopathology, Journal of Clinical Pathology, Leukemia, Leukemia and Lymphoma, and Pathologica. He has authored more than 1,000 scientific reports. Dr. Pileri’s interest is in development and validation of innovative techniques and reagents for hematopathology and oncology.

Anas Younes, MD
Chief, Lymphoma Service
Division of Hematologic Oncology, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed residencies in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, as well as a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Younes is chief of Memorial Sloan Kettering's Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.

Dr. Younes, a board-certified medical oncologist, serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and led the National Cancer Institute–funded SPORE (Specialized Programs of Research Excellence) in lymphoma.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-15-047-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 15-047-018

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Francesco d’Amore has received honoraria related to formal advisory activities from Bayer AG, CTI, and Takeda Oncology. He has received grant support related to research activities from Amgen Inc., F. Hoffmann-La Roche Ltd, and Sanofi.

Dr. Stefano Pileri has received honoraria related to formal advisory activities from Takeda Oncology and the development of educational materials from Medscape.

Dr. Anas Younes has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Janssen Pharmaceuticals, Inc., Sanofi, Seattle Genetics, Inc., and Takeda Oncology. He has received grant support related to research activities from Curis, Inc., Johnson & Johnson Services, Inc., and Novartis AG.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. d’Amore, Pileri, and Younes have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. d’Amore and Pileri have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Dr. Younes has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managinghodgkinlymphoma.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology
MediCom Worldwide, Inc. acknowledges support from The Leukemia & Lymphoma Society

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved